Pfizer, Henlius Biotech and ImmunoGen could this week learn whether the European Medicines Agency will recommend in favor of pan-EU marketing authorization for their respective orphan drugs, marstacimab,serplulimab andmirvetuximab soravtansine.
Marstacimab, Pfizer’s drug for preventing bleeding episodes in patients with hemophilia A or hemophilia B, is also under review in the US, where the Food and Drug Administration is expected...